A different approach better serves patients with diabetic retinopathy

Ciclosporin 0.1% eye drops solution will be marketed under the brand name Vevizye in the EU for the treatment of dry eye disease

Current and future options for Fuchs endothelial corneal dystrophy

Gene therapy was a major topic at the 2024 EURETINA and Retina Society meetings

Dr Yorston delivered the Gisbert Richard Lecture at this year's EURETINA Congress

Srinivas R. Sadda, MD, spoke about the EURETINA meeting, his presentation on ultra widefield imaging, and the value of the international community of retina clinicians connecting in person at meetings. The interview took place at the EURETINA 2024 meeting held in Barcelona, Spain, on September 19-22, 2024.

Taiji Sakamoto, MD, PhD, spoke about being a board member of EURETINA and his motivations to be a part of the cooperative work that is a hallmark of EURETINA. The interview took place at the EURETINA 2024 meeting held in Barcelona, Spain, on September 19-22, 2024.

The e-poster came in 2nd place for the August Deutman award at the EURETINA Congress

Neltependocel has received both regulatory and reimbursement approval in Japan

Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab

Carl Awh, MD, FASRS, spoke the value of the international community of retina clinicians connecting at global meetings

The agency confirmed its June 2024 negative opinion after Apellis requested re-examination of the EMA's initial response

Stefano Mercuri, MD, speaks about his team's August Deutman award-winning research on retinitis pigmentosa and Rho gene mutations

Clare Bailey, MD, shared data from the multi-country study on faricimab for patients with DME and nAMD

Prof Bodaghi praises the ingenuity at this year's EURETINA Innovation Spotlight (EIS)

Enrico Borrelli, MD, FEBO, speaks about opportunities in the retina space